Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

It is with pride and gratitude that we reflect on the remarkable 10-year journey of European Journal of Arrhythmia & Electrophysiology. With the vital contributions of all of our esteemed authors, reviewers and editorial board members, the journal has served as a platform for groundbreaking research, clinical insights and news that have helped shape the […]

Use of a “CNI holidays” strategy in acute renal dysfunction late after heart transplant. Report of two cases

Pau Alonso, Ignacio Sánchez Lázaro, Luis Almenar, Luis Martínez-Dolz, Ana Andres, Antonio Salvador, Anastasio Montero
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Aug 16th 2018 Heart International 2014;9(2):74-77 DOI: https://doi.org/10.5301/HEART.2014.12526
Select a Section…
1

Abstract

Overview

Background. Acute renal dysfunction (ARD) may appear in heart transplant (HTx) patients both in the early
postoperative period and during follow-up, even after several years. CD25 is a subunit of the interleukin-2
receptor which is found exclusively on activated CD4 T lymphocytes. CD25 is crucial for clonal expansion of
anti-allograft host lymphocytes that mediate in acute rejection. There are experiences supporting the use of
Anti-CD25 monoclonal antibodies (MAb) immediately after HTx in patients with ARD as a bridge to renal function
recovery, allowing the temporary suspension of treatment with CNI.
Methods. In this study we report two cases of successful use of weekly MAb (basiliximab) in HTx patients who
developed late ARD after HTx.
Conclusions. In coclusion, we think that in cases of ARD where CNI therapy plays a key role, the use of weekly
doses of basiliximab allows CNI discontinuation until the restoration of renal function is achieved.

Keywords

Basiliximab, CNI holiday, Heart transplant

2

Article Information

Disclosure

Financial support: No grants or funding have been received for this
study.

Correspondence

Pau Alonso La Fe University Hospital Bulevar sur s/n 46008 Valencia Valencia, Spain pau.alonso.fernandez@gmail.com

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Close Popup